DK1674107T3 - Anvendelse af daptomycin - Google Patents

Anvendelse af daptomycin Download PDF

Info

Publication number
DK1674107T3
DK1674107T3 DK06006697.4T DK06006697T DK1674107T3 DK 1674107 T3 DK1674107 T3 DK 1674107T3 DK 06006697 T DK06006697 T DK 06006697T DK 1674107 T3 DK1674107 T3 DK 1674107T3
Authority
DK
Denmark
Prior art keywords
daptomycin
toxicity
skeletal muscle
dose
levels
Prior art date
Application number
DK06006697.4T
Other languages
English (en)
Inventor
Frederick B Oleson Jr
Francis P Tally
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1674107(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Application granted granted Critical
Publication of DK1674107T3 publication Critical patent/DK1674107T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (1)

1. Daptomycin, til anvendelse i behandling afen bakterieinfektion i en human patient med behov derfor, hvor en dosis til denne behandling er 10 mg/kg daptomycin, hvor dosis gentagen administreres i et dosisinterval på én gang hver 5 24. time.
DK06006697.4T 1998-09-25 1999-09-24 Anvendelse af daptomycin DK1674107T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
EP99949913A EP1115417B1 (en) 1998-09-25 1999-09-24 Use of daptomycin

Publications (1)

Publication Number Publication Date
DK1674107T3 true DK1674107T3 (da) 2016-12-19

Family

ID=26798675

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06006697.4T DK1674107T3 (da) 1998-09-25 1999-09-24 Anvendelse af daptomycin
DK99949913T DK1115417T3 (da) 1998-09-25 1999-09-24 Anvendelse af daptomycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99949913T DK1115417T3 (da) 1998-09-25 1999-09-24 Anvendelse af daptomycin

Country Status (26)

Country Link
US (2) US6468967B1 (da)
EP (2) EP1115417B1 (da)
JP (4) JP4184607B2 (da)
KR (2) KR20100051735A (da)
CN (2) CN1530136A (da)
AT (1) ATE322280T1 (da)
AU (1) AU764348B2 (da)
BR (1) BR9914051A (da)
CA (1) CA2344318C (da)
CY (3) CY1105556T1 (da)
DE (3) DE69930758T2 (da)
DK (2) DK1674107T3 (da)
ES (2) ES2259845T3 (da)
HK (1) HK1040363B (da)
HU (1) HU230656B1 (da)
IS (2) IS5890A (da)
LU (1) LU91254I2 (da)
NL (1) NL300232I2 (da)
NO (1) NO20011454L (da)
NZ (1) NZ510690A (da)
PL (2) PL206091B1 (da)
PT (2) PT1115417E (da)
RU (1) RU2363489C9 (da)
SI (2) SI1115417T1 (da)
TR (1) TR200100841T2 (da)
WO (1) WO2000018419A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764348B2 (en) 1998-09-25 2003-08-14 Cubist Pharmaceuticals Llc Methods for administration of antibiotics
KR20020063227A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 신규한 리포펩티드
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20030045678A1 (en) 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
EP3632459A1 (en) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
WO2010048630A1 (en) * 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
EP2674437A1 (en) 2008-12-22 2013-12-18 Cubist Pharmaceuticals, Inc. Novel antibacterial agents for the treatment of GRAM positive infections
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
WO2011008193A1 (en) * 2009-07-13 2011-01-20 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
CN108785654A (zh) 2009-11-23 2018-11-13 丘比斯特制药有限责任公司 脂肽组合物和相关方法
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
EP4066849A1 (en) * 2012-09-11 2022-10-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
EP0386951A3 (en) 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
AU764348B2 (en) 1998-09-25 2003-08-14 Cubist Pharmaceuticals Llc Methods for administration of antibiotics
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
PT1674107T (pt) 2016-12-07
EP1115417B1 (en) 2006-04-05
DK1115417T3 (da) 2006-07-31
JP2006335773A (ja) 2006-12-14
KR20100051735A (ko) 2010-05-17
RU2004106569A (ru) 2005-08-10
KR20010075327A (ko) 2001-08-09
EP1674107B1 (en) 2016-08-24
HUP0103874A2 (hu) 2002-02-28
NL300232I1 (nl) 2006-09-01
RU2363489C2 (ru) 2009-08-10
EP1674107A2 (en) 2006-06-28
CY2006003I2 (el) 2009-11-04
CA2344318C (en) 2006-07-04
PT1115417E (pt) 2006-07-31
DE122006000049I1 (de) 2007-01-04
HK1040363B (zh) 2007-01-26
NO20011454L (no) 2001-05-25
ATE322280T1 (de) 2006-04-15
JP4184607B2 (ja) 2008-11-19
LU91254I2 (fr) 2006-08-28
CN1530136A (zh) 2004-09-22
CY1105556T1 (el) 2010-07-28
PL203689B1 (pl) 2009-11-30
CY2006003I1 (el) 2009-11-04
DE69930758D1 (de) 2006-05-18
BR9914051A (pt) 2001-06-19
ES2603086T3 (es) 2017-02-23
EP1674107A8 (en) 2006-10-04
JP2002525335A (ja) 2002-08-13
AU6268799A (en) 2000-04-17
AU764348B2 (en) 2003-08-14
CN1150029C (zh) 2004-05-19
DE122006000049I2 (de) 2007-11-08
ES2259845T3 (es) 2006-10-16
WO2000018419A2 (en) 2000-04-06
DE69930758T2 (de) 2007-04-26
US6852689B2 (en) 2005-02-08
SI1674107T1 (sl) 2017-01-31
US20020142948A1 (en) 2002-10-03
CA2344318A1 (en) 2000-04-06
NZ510690A (en) 2002-10-25
NL300232I2 (nl) 2007-01-02
HU230656B1 (hu) 2017-06-28
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
RU2363489C9 (ru) 2010-03-20
EP1674107A3 (en) 2012-06-20
WO2000018419A3 (en) 2000-07-06
EP1674107B8 (en) 2017-01-25
US6468967B1 (en) 2002-10-22
IS5890A (is) 2001-03-14
HUP0103874A3 (en) 2002-09-30
CN1348382A (zh) 2002-05-08
HK1040363A1 (en) 2002-06-07
PL348328A1 (en) 2002-05-20
TR200100841T2 (tr) 2002-01-21
JP2003321389A (ja) 2003-11-11
IS8807A (is) 2009-03-10
PL206091B1 (pl) 2010-06-30
NO20011454D0 (no) 2001-03-22
JP2004339238A (ja) 2004-12-02
SI1115417T1 (sl) 2006-08-31

Similar Documents

Publication Publication Date Title
DK1674107T3 (da) Anvendelse af daptomycin
Rybak The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram‐positive bacteria
Zhanel et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin
Tally et al. Daptomycin: a novel agent for Gram-positive infections
Finch et al. Safety and efficacy of glycopeptide antibiotics
Tedesco et al. Daptomycin
Nigo et al. What’s new in the treatment of enterococcal endocarditis?
Leonard et al. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram‐positive infections
Biondi et al. From Natural products to drugs: Glyco-and lipoglycopeptides, a new generation of potent cell wall biosynthesis inhibitors
RU2232592C2 (ru) Способ лечения бактериальной инфекции
Janknegt Teicoplanin in perspective: A critical comparison with vancomycin
Ross et al. Glycopeptide pharmacodynamics
CZ20011014A3 (cs) Farmaceutické přípravky obsahující lipoproteinová antibiotika
Sun et al. Daptomycin
Wenzler et al. Pharmacodynamics of lipoglycopeptides
Raja et al. Fresh from the pipeline
Schneider et al. Friulimicin inhibits cell wall biosynthesis through complex formation with bactoprenol-phosphate
Chopra et al. Murepavadin. Outer membrane protein-targeting antibiotic, Inhibitor of LptD-mediated lipopolysaccharide (LPS) transport, Treatment of Pseudomonas aeruginosa respiratory infections
Ziglam et al. New therapeutic agents for resistant Gram-positive infections
Jacqueline et al. Antibiotics Against Endocarditis–Past, Present and Future (Experimental Data)
Shankar et al. Newer antibiotics
EA007713B1 (ru) Ассоциации дальфопристин/хинупристин с цефпиромом